New Nordisk patent expiration paves way for affordable weight loss drug in India
Novo Nordisk India’s patent on semaglutide expires this week Ride the wave of cheap generics from local drugmakers Concerns have been raised about abusive, unequal supervision HYDERABAD, March 19 (Reuters) – India’s diabetes and weight loss drug market is poised for a shake-up as Danish drugmaker Novo Nordisk ( NOVOb.CO )opens a new tab Semaglutide’s … Read more